Whatever about how OSL has handled this, I think Hogan made a very good point in the Australian article:
“I’m not sure that if you’re an executive director of one company, whether you should be commentating on others in the same industry. All these biotech companies are competing for the same pools of capital.’’
This is absolutely correct. Behrenbruch claims that he has "refrained from commenting on Factor Therapeutics or any of its competitors", but his blog is in fact specifically focussed on companies that compete with Factor Therapeutics for essentially the same pool of investors.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
0.025(2.30%) |
Mkt cap ! $20.89M | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.11 | $1.09 | $26.73K | 24.35K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6807 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.12 | 6617 | 1 |
View Market Depth
| Last trade - 16.10pm 07/08/2025 (20 minute delay) ? |
| OSL (ASX) Chart |